Abstract: The present invention relates to orally administered suspensions of pharmaceutical active substances of the NSAID type, particularly the antirheumatic agent Meloxicam, which are stabilized by the addition of small amounts of highly dispersed silicon dioxide using high shear forces and adding small amounts of hydrophilic polymers to form a three-dimensional siloid structure, and a process for the preparation thereof.

Abstract: A stable, solid product of selected starches, active agricultural agents and optionally surfactants and or adjuvants which is readily dispersible in aqueous medium and compatible when dispersed.

Abstract: This invention is directed to pharmaceutical compositions for oral administration, wherein the drug or active ingredient is known to have stability problems associated with the use of free fatty acids. The compositions of the invention enhance the solubility of such compounds and improve the storage stability thereof and can be advantageously used in soft-gel and hard-shell capsular formulations. The liquid pharmaceutical compositions, according to the present invention, have a drug dissolved in a liquid vehicle. The liquid vehicle comprising a glyceride of a long chain fatty acid and a lypophilic surfactant having an HLB of less than ten. The composition, according to the invention, is also substantially free of free fatty acids.

Abstract: The invention is directed to therapeutic antioxidant compositions which are enhanced by the stabilized atomic hydrogen; one of the most potent antioxidants. Such products can be used for prophylactic and therapeutic purposes in treatment of cancer, diabetes, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases, skin diseases etc. The products described can be used independently or in combination with other drugs and treatment modalities. The products can also be used as dietetic products to aid in desired weigh loss. The described products can also be used to prevent oxidative and free radical damage to food and oxidation-prone industrial products. The invention also describes the methods to produce and stabilize atomic hydrogen and prepare and use such stabilized/encaged atomic hydrogen enhanced antioxidant compositions.

Abstract: The present invention relates to insect repellant compositions containing, based upon the total weight of the composition, from about 6 to about 30 percent by weight of insect repellant active material having functionality selected from ester, amide, urethane or combinations thereof; from about 5 to about 30 percent by weight of alcohol, and from about 1 to about 10 percent by weight of nonionic surfactant. The compositions of the invention exhibit reduced rates of degradation of the active material in solution and are less drying and irritating to sensitive skin.

Abstract: A method of treating plant and animal systems and inanimate surfaces for the purposes of controlling plant pests, introducing pesticides and nutrients into plants, mitigating frost damage to plants, increasing crop yields, controlling certain plant diseases, controlling arthropod, bacterial, fungal, mycoplasma, rickettsia, and viral pests of animals and humans, and disinfecting inanimate surfaces. The method utilizes the unique multi-directional dispersion property of the tannate complex of picro ammonium formate and the tannate complex of picro cupric ammonium formate, in aqueous solution, combined with a minor amount of a surfactant sufficient to prevent formation of ammonium picrate, to penetrate plant and animal systems and inanimate surfaces and travelling multidirectionally therein. The method is carried out by introducing a small but effective amount of the tannate complex to the plant or animal system or inanimate surface.

Abstract: A method of increasing the shelf life of silicone hydrogels stored in aqueous solutions. More specifically, the present invention relates to a method of stabilizing a silicone hydrogel article against hydrolytic degradation comprising, storing said silicone hydrogel in an ozone-free, aqueous solution having a pH of from about 5.0 to less than about 7.2, and a viscosity of less than about 10 centipoise, wherein if the aqueous solution is substantially free of poloxamine or poloxamer surfactants.

Abstract: A method of dyeing and treating a substrate using a water-stabilized organosilane. A method of antimicrobially treating a food article. A method of antimicrobially coating a fluid container. A method of antimicrobially coating a latex medical article.

Abstract: Coloring change of a pharmaceutical composition containing a compound having a phenolic hydroxyl group, such as an anti-inflammatory agent or an antioxidant having a phenolic hydroxyl group or the compound of formula (I) can be controlled by adding an acid. The present invention provides a pharmaceutical composition containing a compound having a phenolic hydroxyl group and an acid in which coloring change is controlled.

Abstract: In producing aqueous microbiocidal solutions by oxidation of a water-soluble alkali metal bromide, an intolerable loss of active halogen species has been found to occur during a 10-day period immediately after the product solution has been formed. Surprisingly, this loss has been found to result from an alcohol impurity in the alkali metal bromide used in the process. By eliminating or at least sharply reducing the amount of alcohol impurity in the reaction mixture, products are formed which do not undergo the intolerable loss of active halogen content during the 10-day period.

Abstract: A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.

Abstract: A method for the preparation of a stable, liquid formulation of growth hormone, comprising growth hormone, a buffer and a stabilizing effective amount of at least one stabilizing agent selected from the group consisting of: (i) polyethylene-polypropylene glycol non-ionic surfactants, (ii) taurocholic acid or salts or derivatives thereof, and (iii) methyl cellulose derivatives, wherein the method comprises admixing the growth hormone with the buffer and the stabilizing agent(s) under conditions such that the growth hormone is not exposed to concentrations of the buffer or stabilizing agent(s) which are greater than 2× the final concentrations of the buffer or stabilizing agent(s) in the formulation.

Abstract: There is disclosed a method for stabilizing active substances that are unstable in acidic medium, unstable when stored for longer periods of time in the presence of water and at the same time sensitive to heating, by means of anhydrous granulation of active substances and dried pharmaceutically acceptable auxiliary substances for the preparation of pellet cores or granules. All pharmaceutically acceptable auxiliary substances employed are dried before use so that their weight loss at drying is less than 1.0% of the total weight of the pharmaceutically acceptable auxiliary substance, preferably less than 0.5%. Organic solvents used in process of anhydrous granulation should contain less than 0.2% of water. A novel pharmaceutical formulation with controlled release of active substances that are unstable in acidic medium, unstable when stored for longer periods of time in the presence of water and at the same time sensitive to heating, is disclosed as well.

Abstract: Anhydrous, liquid antimicrobial compositions comprising quaternaries 1-(benzyl)-3,5,7-triaza-1-azoniaadamantane chloride, 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride and the cis- and cis/trans-isomers thereof, 1-(&agr;-(2-xylyl))-3,5,7-triaza-1-azoniaadamantane chloride and methyl 1-(3,5,7-triaza-1-azoniaadamantane chloride) acetate in admixture with an anhydrous carrier liquid and a thixotropic material are substantially stable to color changes, physical changes and/or chemical changes while under conventional storage conditions for extended time periods.

Abstract: The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.

Abstract: A topical composition for skin treatment comprising about 60.001% to 1% by weight of a retinoid solubilizer and/or stabilized with preferably about 0.1% to about 50% by weight of a diester or polyester of a naphthalene dicarboxylic acid having compound formula (I), (II), (III) or mixtures: wherein R1 is an alkyl group, straight chain or branched, having 1 to 22 carbon atoms; wherein each R1, same or different, is an alkyl group having 1 to 22 carbon atoms, a diol having the structure HO—R2—OH, or a polyglycol having the structure HO—R3—(—O—R2—)m—OH wherein R2 and R3, same or different, are each an alkylene group, straight chain or branched, having 1 to 6 carbon atoms, and wherein m and n are each 1 to about 100, or a mixture thereof.

Abstract: A stabilized insect mating disruption pheromone compositions comprising an insect pheromone and 2,2′-Methylenebis(6-t-butyl-p-cresol). Methods of use and microcapsules containing these compositions are also provided.

Abstract: A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid and an optional oxidizable colorant, and wherein the first part, the second part, or both the first and second parts comprise an alpha olefin sulfonate.

Abstract: This invention relates to disinfectant concentrates having improved biocidal activity containing an aldehyde, such as glutaraldehyde, a glycol and a lithium based buffer.

Abstract: A composition for human consumption, comprising creatine and creatinine, the latter being in sufficient quantity to render creatine in an aqueous medium substantially stable, and a method of making the composition is provided.

Abstract: A controlled release diltiazem dosage formulation comprising a plurality of active pellets coated with an extended release coating wherein the active pellets contain diltiazem or a pharmaceutically acceptable salt, a pharmaceutically acceptable inert seed and a binder and the extended release coating contains a water insoluble water permeable polymer, a channeling agent, a lubricant and optionally a surfactant. A single batch intermittent method of manufacturing a heterogeneous population of extended release pellets for use as a dosage formulation is also disclosed.

Abstract: Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. The compositions are near isotonic. Methods for increasing stability of a polypeptide in a liquid pharmaceutical composition and for increasing storage stability of such a pharmaceutical composition are also provided.

Abstract: A device for the sustained release in vivo of a water soluble, biologically active agent wherein the agent is susceptible to aggregation comprising a drug delivery device and aggregation-stabilized, biologically active agent wherein the aggregation-stabilized agent is disposed within the drug delivery device.

Abstract: The present invention provides a virucide composition and/or sporicide composition having a high virucidal effect and sporicidal effect and being excellent in safety and workability. That is, the present invention provides a virucide composition and/or sporicide composition comprising (a) an inorganic peroxide, (b) tetraacetylethylenediamine and (c) at least one selected from a salt of an alkaline metal salt with an inorganic acid and a salt of an alkaline earth metal with an inorganic acid in a specific ratio.

Abstract: The present invention relates to a volatile, residue free peroxide antimicrobial composition, which can be applied as a penetrating and durable, fine aerosol, that has superior strength with respect to decontaminating buildings infected with bacteria, fungi, virus or fungal or bacterial spores. The present invention is also directed to a process for decontaminating large man made structures and the air contained in these.

Abstract: The invention relates to a pharmaceutical preparation comprising levothyroxine sodium, potassium iodide, microcrystalline cellulose and binding agent, which is free of antioxidants or further auxiliaries, and processes for its production.

Abstract: The present invention provides methods for preparing, and compositions comprising, stabilized protein-polymer conjugates. More particularly, the present invention relates to the stabilization of individual subunits of multisubunit protein complexes by conjugation to polymers. Such conjugation acts to stabilize the individual subunit in its native conformation in liquid medium, which in turn acts to stabilize its biological activity.

Abstract: Antimicrobial/pharmaceutical preparations (e.g., solutions, gels, ointments, creams, sustained release preparations, etc.) which comprise chlorite (e.g., a metal salt of a chlorite) in combination with a peroxy compound (e.g., hydrogen peroxide), and methods for using such preparations for disinfection of articles or surfaces (e.g., contact lenses, counter tops, etc.), antisepsis of skin or other body parts, prevention or deterrence of scar formation and/or treatment and prophylaxis of dermal (i.e., skin or mucous membrane) disorders (e.g., wounds, burns, infections, cold sores, ulcerations, psoriasis, acne, or other scar-forming lesions).

Abstract: This invention in general relates to novel pharmaceutical compositions for acid labile substances as well as for methods of making such. Specifically, the invention provides a pharmaceutical composition comprising about 1 to 75% by weight acid labile compound, up to about 5% by weight disintegrant, at least one protector coat layer used to separate and protect the acid labile substance from acid reacting groups and gastric juice, and at least one enteric coat layer which surrounds the protector coating layer and ensures delivery of over 80% the acid labile substance to the small intestine.

Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.

Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.

Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.

Abstract: Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-[4′-4″-fluorophenyl-2′-cyclopropyl-quinolin-3′-yl]-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has pH of from 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.

Abstract: Liquid germicidal formulation containing, as the active ingredients, a combination of an alcohol and an organic N-chloroamine, which combination shows a high bactericidal activity and an unexpected stability in time, while maintaining its effectiveness substantially unchanged even after a prolonged storage. The formulation comprises, in water, chloramine-T or chloramine-B and one or more, aliphatic alcohols having up to 12 carbon atoms, preferably isopropanol, said solution having a pH not lower than 8.5.

Abstract: A cosmetic composition is provided which includes at least about 2% solid asymmetric particles, a retinoid solubilized in a fluid oil and wherein the fluid oil to solid particles are present in a weight ratio such that the composition exhibits a normal force value of less than −100 milli-Newton containing a retinoid. The composition diminishes the appearance and feel of oily skin and is capable of delivering benefits associated with retinoids.

Abstract: An adjuvant composition, comprising a metabolizable oil and an emulsifying agent, wherein the oil and the detergent are present in the form of an oil-in-water emulsion having oil droplets substantially all of which are less than 1 micron in diameter. In preferred embodiments, the emulsifying agent is also an immunostimulating agent, such as a lipophilic muramyl peptide. Alternatively, an immunostimulating agent separate from the emulsifying agent can be used.

Abstract: Particles of a substantially water insoluble biologically active substance, such as Cyclosporin, are loaded with a charged glyceryl ester as an electrostatic stabilizer which imparts to the particles a zeta potential and having an active substance:stabilizer weight ratio of 1:1 to 400:1 and an average particle diameter of 1 nanometer to 10 micrometers. Compositions having such particles are found to be useful delivery systems.

Abstract: The present invention provides an improved soft chewable multivitamin tablet in which vitamin C is separated from calcium pantothenate and/or minerals such as iron, copper, zinc and mixtures thereof in a core or multilaminate form and a process for preparing the same. The soft chewable multivitamin tablet of the present invention maintains its stability over a long-storage time in terms of the content and potency of vitamins while overcoming the problems of incompatibility, bad mouthfeel and palatability.

Abstract: Composition in the form of an aqueous solution, useful for disinfecting hard surfaces comprises: a) from 0.0005% to 20% by weight of peracetic acid, b) from 0.001% to 45% by weight of acetic acid, c) from 0.001% to 35% by weight of hydrogen peroxide, d) from 0.0001% to 2% by weight of at least one compound of formula (I) (R1)(R2)(R3)N→O  (I) e) if desired, up to 2.5% by weight of at least one nonionic surfactant, and wherein f) the weight ratio between the compound of formula (I) and the peracetic acid is less than or equal to 1, and in that g) the weight ratio between the nonionic surfactant and the peracetic acid is less than or equal to 0.2.

Abstract: The present invention provides a composition for attracting scarabs. Liquid and solid formulations are provided, along with methods for their use, for controlling or eliminating scarabs, and/or protecting plants susceptible to scarab damage.

Abstract: The present invention provides an improved soft chewable multivitamin tablet in which vitamin C is separated from calcium pantothenate and/or minerals such as iron, copper, zinc and mixtures thereof in a core or multilaminate form and a process for preparing the same. The soft chewable multivitamin tablet of the present invention maintains its stability over a long-storage time in terms of the content and potency of vitamins while overcoming the problems of incompatibility, bad mouthfeel and palatability.

Abstract: A disinfectant composition containing more than 0.05% and less than 9.4% by volume of dimethyl benzyl lauryl ammonium bromide, substantially pure, substantially de-ionized, substantially bacteria free water if the pH of the water is between 5.0 and 6.8, a first stabilizer structured to adjust a pH level of the disinfectant composition to approximately 7, ammonium Bulfate structured to increase a strength of the composition and a stabilizer structured to lower the pH level of the disinfectant composition back to approximately 7.

Abstract: The present invention is directed to a pharmaceutical composition, preferably in the form of a tablet comprising a therapeutically effective amount of a medicament in a carrier comprising a water insoluble polymer and a water-insoluble inorganic salt.

Abstract: A mixed micellar aerosol pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal lauryl sulphate, at least three micelle forming compounds, a phenol and a propellant. The micelle forming compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof. The amount of each micelle forming compound is present in a concentration of from 1 to 20 wt./wt. % of the total formulation, and the total concentration of micelle forming compounds are less than 50 wt./wt. % of the formulation.

Abstract: A method including administering a beverage composition suitable for human consumption including effective amounts of the following solubilized components, a calcium compound, an organic acid in an amount up to the equivalent amount of a calcium of the calcium compound, an isoflavone, and inulin wherein the effective amounts are sufficient to reduce the risk of bone density loss and are solubilized by a stabilizing agent including one or more of maltol, carrageenan and maltodextrin, and xanthan gum.

Abstract: A method for producing a suspension, emulsion or dispersion of de-agglomerated particles (advantageously submicron-sized particles) of pyrithione salts comprising contacting agglomerated pyrithione salt particles with a de-agglomerating agent to produce the desired de-agglomerated pyrithione salt particles. Also disclosed is a method for making de-agglomerated submicron-sized particles of pyrithione salts comprision a heating step. Also disclosed are the particles made by the above methods and compositions comprising the particles and a base medium.

Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceuticalexcipient, to the formulation. The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceuticalexcipient. The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.

Abstract: Compounds having thrombin inhibiting activity of the general formula I or II where n is 0.5, 1, 2 and HX is  and HX is optionally substituted once or twice by methyl, ethyl or hydroxyl, and the tautomers and stereoisomers thereof, which compounds have greater thermal stability betaines, and salts of mineral acids or C1-C4-carboxylic acids.

Abstract: A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.

Abstract: A material or mixture of materials which is not itself storage stable is rendered storage stable by incorporation into a water-soluble or swellable glassy or rubbery composition which can then be stored at ambient temperature. Recovery is by adding aqueous solution to the composition.